Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction

Annals of Oncology

Volumn 11, Issue 9, 2000, Pages 1161-1164

  Sandler, A B ^a   Kindler, H L ^b   Einhorn, L H ^a   Mitchell, E ^c   Masters, G ^d   Kraut, M ^e   Nicol, S ^f   Raghavan, D ^b  

^a INDIANA UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Chemotherapy; Esophageal cancer; Gemcitabine

Indexed keywords

GEMCITABINE; LY 18801;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE CALCULATION; DRUG TOLERABILITY; ESOPHAGUS CANCER; ESOPHAGUS METASTASIS; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0033791494     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008369718242     Document Type: Article

References (20)

1. Cancer statistics
2. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary
3. Esophageal cancer
4. Phase II trial of vinorelbine in metastatic squamous-cell esophageal carcinoma
5. Activity of Taxol in patients with squamous-cell carcinoma
6. Synthesis of 2-deoxy-2',2'-difluoro-D-ribose and 2-deoxy-2',2'-difluoro-D-ribofuranosyl nucleosides
7. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
8. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
9. Gemcitabine in advanced breast cancer
10. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients
11. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
12. Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer. National Cancer Institute of Canada Clinical Trials Group
13. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small-cell lung cancer: An overview
14. One-sample multiple testing procedure for phase II clinical trials
15. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
16. Overview: The changing nature of esophageal cancer
17. A phase II study of gemcitabine (LY188011) in patients with advanced squamous-cell carcinoma of the head and neck
18. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer
19. Phase II study of gemcitabine in advanced colorectal adenocarcinoma
20. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus